Rilapladib is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor that functions by targeting an enzyme associated with the development of atherosclerotic plaques in the arteries. As an investigational… Read more
Rilapladib is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor that functions by targeting an enzyme associated with the development of atherosclerotic plaques in the arteries. As an investigational small molecule developed for the potential treatment of cardiovascular diseases, maintaining high analytical precision throughout its lifecycle is critical. This category provides a comprehensive selection of Rilapladib reference standards, including pharmacopeial and non-pharmacopeial impurities, as well as stable isotope-labelled compounds. These materials are essential for pharmaceutical laboratories conducting rigorous impurity profiling, method validation, and stability testing. By utilizing these high-quality standards, researchers can ensure accurate quantification and characterization of the drug substance and its related substances, thereby supporting the stringent quality control protocols required during drug development and regulatory assessment.